Search Results - "Servitja, Sonia"

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy by Muntasell, Aura, Cabo, Mariona, Servitja, Sonia, Tusquets, Ignasi, Martínez-García, María, Rovira, Ana, Rojo, Federico, Albanell, Joan, López-Botet, Miguel

“…Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of…”
Get full text

Incidence of complications associated to bile duct stents, in patients with advanced cancer: a single-center experience by Corbera, Alex, Rios-Hoyo, Alejandro, Visa, Laura, Casadevall, David, Ilzarbe, Lucas, Barranco, Luis, Radosevic, Aleksandar, Servitja, Sonia

“…Background Pancreatic cancer (PCa) and biliary tract carcinomas (BTCa) have high morbidity and mortality rates. Bile duct obstruction (BDO) develops in…”
Get full text

Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study) by González-Santiago, Santiago, Saura, Cristina, Ciruelos, Eva, Alonso, José Luis, de la Morena, Pilar, Santisteban Eslava, Marta, Gallegos Sancho, Maria Isabel, de Luna, Alicia, Dalmau, Elsa, Servitja, Sonia, Ruiz Borrego, Manuel, Chacón, José Ignacio

“…Purpose Neoadjuvant clinical trials with dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy demonstrated high rates of pathological complete…”
Get full text

Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study by Pineda-Moncusí, Marta, Garcia-Giralt, Natalia, Diez-Perez, Adolfo, Tusquets, Ignasi, Servitja, Sonia, Albanell, Joan, Prieto-Alhambra, Daniel, Nogués, Xavier

“…Background: Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events,…”
Get full text

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer by Santana-Hernández, Sara, Suarez-Olmos, Jesús, Servitja, Sonia, Berenguer-Molins, Pau, Costa-Garcia, Marcel, Comerma, Laura, Rea, Anna, Perera-Bel, Julia, Menendez, Silvia, Arpí, Oriol, Bermejo, Begoña, Martínez, María Teresa, Cejalvo, Juan Miguel, Comino-Méndez, Iñaki, Pascual, Javier, Alba, Emilio, López-Botet, Miguel, Rojo, Federico, Rovira, Ana, Albanell, Joan, Muntasell, Aura

“…The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative…”
Get full text

Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers by Domingo, Laia, Blanch, Jordi, Servitja, Sònia, Corominas, Josep Maria, Murta-Nascimento, Cristiane, Rueda, Antonio, Redondo, Maximino, Castells, Xavier, Sala, Maria

“…The question of whether screen detection confers an additional survival benefit in breast cancer is unclear and subject to several biases. Our aim was to…”
Get full text

Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain by Domingo, Laia, Sala, Maria, Servitja, Sònia, Corominas, Josep Maria, Ferrer, Francisco, Martínez, Juan, Macià, Francesc, Quintana, Maria Jesús, Albanell, Joan, Castells, Xavier

“…Objective To analyze phenotypic classification and other risk factors for interval breast cancer, focusing on true interval and false negative cancers. Methods…”
Get full text

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study by Garcia-Giralt, Natalia, Rodríguez-Sanz, María, Prieto-Alhambra, Daniel, Servitja, Sonia, Torres-del Pliego, Elisa, Balcells, Susana, Albanell, Joan, Grinberg, Daniel, Diez-Perez, Adolfo, Tusquets, Ignasi, Nogués, Xavier

“…A major side effect of aromatase inhibitor (AI) therapy is AI-related arthralgia (AIA), which often leads to therapy discontinuation. We aimed to identify…”
Get full text

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance by Servitja, Sonia, Martos, Tamara, Rodriguez Sanz, Maria, Garcia-Giralt, Natalia, Prieto-Alhambra, Daniel, Garrigos, Laia, Nogues, Xavier, Tusquets, Ignasi

“…Aromatase inhibitors (AIs) are routinely used in the adjuvant treatment of women with hormone receptor-positive early breast cancer. Patients who receive AIs…”
Get full text

Factors affecting 5- and 10-year survival of women with breast cancer: An analysis based on a public general hospital in Barcelona by Macià, Francesc, Porta, Miquel, Murta-Nascimento, Cristiane, Servitja, Sònia, Guxens, Mònica, Burón, Andrea, Tusquets, Ignasi, Albanell, Joan, Castells, Xavier

“…Abstract Background Data from a long-established hospital-based cancer registry were used to analyse the relationship between clinical and organisational…”
Get full text

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer by Servitja, Sònia, Nogués, Xavier, Prieto-Alhambra, Daniel, Martínez-García, María, Garrigós, Laia, Peña, María Jesús, de Ramon, Marta, Díez-Pérez, Adolfo, Albanell, Joan, Tusquets, Ignasi

“…Abstract Objective Baseline bone health in postmenopausal women is poorly characterized in prospective series of early breast cancer (EBC) patients candidates…”
Get full text

Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin by ROJO, Federico, GONZALEZ-NAVARRETE, Irene, SANCHEZ-PEREZ, Isabel, CAMPAS, Clara, COROMINAS, Josep Maria, TUSQUETS, Ignasi, BELLOSILLO, Beatriz, SERRANO, Sergi, PERONA, Rosario, ROVIRA, Ana, ALBANELL, Joan, BRAGADO, Rafael, DALMASES, Alba, MENENDEZ, Silvia, CORTES-SEMPERE, Maria, SUAREZ, Cristina, OLIVA, Cristina, SERVITJA, Sonia, RODRIGUEZ-FANJUL, Vanesa

“…Purpose: Mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) dephosphorylates mitogen-activated protein kinase [extracellular signal-regulated kinase…”
Get full text

Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer by Tusquets Trías de Bes, Ignasi, Servitja Tormo, Sònia, Albanell Mestres, Joan

“…Abstract Women are at considerable risk of recurrence in the first few years following initial treatment for early breast cancer. To reduce the risk of…”
Get full text

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer by Dalmases, Alba, González, Irene, Menendez, Silvia, Arpí, Oriol, Corominas, Josep Maria, Servitja, Sonia, Tusquets, Ignasi, Chamizo, Cristina, Rincón, Raúl, Espinosa, Lluis, Bigas, Anna, Eroles, Pilar, Furriol, Jessica, Lluch, Anna, Rovira, Ana, Albanell, Joan, Rojo, Federico

“…NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer…”
Get full text

Characterization and Spatial Distribution of the Immune Cell Infiltrate in Triple-Negative Breast Cancer: A Novel Classification based on Plasma Cells and CD8+ T cells by Gonzàlez-Farré, Mònica, Gibert, Joan, Santiago, Pablo, Menéndez, Silvia, Montzonis, Xavier, Olivares, Francesc, Riera, Xènia, López, David, Torner, Ariadna, Casado, Beatriz, Bellosillo, Beatriz, Lloveras, Belén, Casadevall, David, Rovira, Ana, Servitja, Sònia, Albanell, Joan, Vázquez, Ivonne, Comerma, Laura

“…Stromal tumor infiltrating lymphocytes (sTIL) are a robust prognostic and predictive biomarker in triple negative breast carcinoma (TNBC). However, the sTIL…”
Get full text

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial by Pérez-García, José Manuel, Vaz Batista, Marta, Cortez, Patricia, Ruiz-Borrego, Manuel, Cejalvo, Juan Miguel, de la Haba-Rodriguez, Juan, Garrigós, Laia, Racca, Fabricio, Servitja, Sonia, Blanch, Salvador, Gion, María, Nave, Monica, Fernández-Abad, María, Martinez-Bueno, Alejandro, Llombart-Cussac, Antonio, Sampayo-Cordero, Miguel, Malfettone, Andrea, Cortés, Javier, Braga, Sofía

“…Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy…”
Get full text

Changes in mammographic density over time and the risk of breast cancer: An observational cohort study by Román, Marta, Sala, Maria, Baré, Marisa, Posso, Margarita, Vidal, Carmen, Louro, Javier, Sánchez, Mar, Peñalva, Lupe, Castells, Xavier, Burón, Andrea, Castells, Xavier, Domingo, Laia, Louro, Javier, Posso, Margarita, Rodríguez-Arana, Ana, Román, Marta, Sala, Maria, Servitja, Sònia, Vernet, Mar, Andreu, Xavier, Baré, Marisa, Benito, Llucia, Vidal, Carmen, Quintana, María Jesús, Solà-Roca, Judit, Sánchez, Mar, Prieto, Miguel, Galceran, Jaume, Saladié, Francina, Ferrer, Joana, Espinàs, Josep Alfons, Peñalva, Lupe, Torá-Rocamora, Isabel, Bargalló, Xavier

“…The effect of changes in mammographic density over time on the risk of breast cancer remains inconclusive. We used information from four centres of the Breast…”
Get full text

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP) by Manso, Luis, Hernando, Cristina, Galán, María, Oliveira, Mafalda, Cabrera, Miguel A., Bratos, Raquel, Rodríguez, César A., Ruiz-Borrego, Manuel, Blanch, Salvador, Llombart-Cussac, Antonio, Delgado-Mingorance, Juan I., Álvarez-Busto, Iñaki, Gallegos, Isabel, González-Cortijo, Lucía, Morales, Serafín, Aguirre, Elena, Hernando, Blanca A., Ballesteros, Ana, Alés-Martínez, José E., Reboredo, Cristina, Oltra, Amparo, González-Cao, María, Santisteban, Marta, Malón, Diego, Echeverría, Isabel, García-Garre, Elisa, Vega, Estela, Servitja, Sònia, Andrés, Raquel, Robles, Carlos E., López, Rafael, Galve, Elena, Echarri, María J., Legeren, Marta, Moreno, Fernando

“…This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor…”
Get full text

NK Cell Infiltrates and HLA Class I Expression in Primary HER2 + Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival by Muntasell, Aura, Rojo, Federico, Servitja, Sonia, Rubio-Perez, Carlota, Cabo, Mariona, Tamborero, David, Costa-García, Marcel, Martínez-Garcia, María, Menéndez, Sílvia, Vazquez, Ivonne, Lluch, Ana, Gonzalez-Perez, Abel, Rovira, Ana, López-Botet, Miguel, Albanell, Joan

“…We investigated the value of tumor-infiltrating NK (TI-NK) cells and HLA class I tumor expression as biomarkers of response to neoadjuvant anti-HER2…”
Get full text

Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients by Valentí Moreno, Vicente, Brunet Vidal, Joan, Manzano Alemany, Hermini, Salud Salvia, Antonia, Llobera Serentill, Montserrat, Cabezas Montero, Inés, Servitja Tormo, Sonia, Sopena Bert, Eugenia, Gumà Padró, Josep

“…Intestinal alkalization could prevent irinotecan associated diarrhea modulating some chemical equilibria between irinotecan metabolites. The aim of this study…”
Get full text